Trial Profile
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients With Moderate-to-Severe Genital Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IXORA-Q
- Sponsors Eli Lilly and Company
- 08 Oct 2019 According to an Eli Lilly media release, data from this study will be presented at the upcoming 28th annual European Academy of Dermatology and Venereology (EADV) Congress taking place Oct. 9-13 in Madrid, Spain.
- 01 Mar 2019 According to an Eli Lilly media release, results from this study will be presented at the American Academy of Dermatology (AAD) annual meeting 2019.
- 22 May 2018 Results presented in the Eli Lilly media release.